Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFMW) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Sunshine Biopharma (SBFMW) over the last 14 years, with Q3 2025 value amounting to -$883820.0.

  • Sunshine Biopharma's Profit After Tax rose 2621.32% to -$883820.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 4180.64%. This contributed to the annual value of -$5.1 million for FY2024, which is 1393.84% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Profit After Tax of -$883820.0 as of Q3 2025, which was up 2621.32% from -$1.8 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Profit After Tax peaked at $667116.0 during Q4 2021, and registered a low of -$23.5 million during Q4 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$1.3 million (2023), whereas its average is -$2.8 million.
  • Over the last 5 years, Sunshine Biopharma's Profit After Tax had its largest YoY gain of 16155.38% in 2021, and its largest YoY loss of 646184.13% in 2021.
  • Sunshine Biopharma's Profit After Tax (Quarter) stood at $667116.0 in 2021, then tumbled by 3624.47% to -$23.5 million in 2022, then soared by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then skyrocketed by 59.05% to -$883820.0 in 2025.
  • Its Profit After Tax was -$883820.0 in Q3 2025, compared to -$1.8 million in Q2 2025 and -$1.2 million in Q1 2025.